Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

T cells in myeloma.

M Raitakari1, R D Brown, J Gibson

  • 1Department of Clinical Chemistry, Turku University Central Hospital, Turku, Finland.

Hematological Oncology
|February 28, 2003
PubMed
Summary

Immunotherapy for myeloma shows promise, but T cell responses are challenging. Further research is needed to identify tumor antigens and enhance T cell activity for better myeloma treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD10-(CALLA)-Positive Lymphocytes in Myeloma: Evidence that they are a Malignant Precursor Population and are of Germinal Centre Origin.

Leukemia & lymphoma·2016
Same author

Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance.

Blood cancer journal·2013
Same author

Leukaemias into the 21st century. Part 2: the chronic leukaemias.

Internal medicine journal·2013
Same author

Performance evaluation of the Abbott CELL-DYN Emerald for use as a bench-top analyzer in a research setting.

International journal of laboratory hematology·2013
Same author

Leukaemias into the 21st century: part 1: the acute leukaemias.

Internal medicine journal·2012
Same author

Exome sequencing in tracking clonal evolution in multiple myeloma following therapy.

Leukemia·2012

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Immunotherapy is a growing strategy for myeloma and B cell malignancies.
  • Expanded T cell clones in myeloma patients correlate with improved survival.
  • Clinical trials for myeloma immunotherapy have yielded limited success.

Purpose of the Study:

  • To investigate the functional state of T cells in myeloma patients.
  • To understand the challenges in isolating tumor-specific T cells for immunotherapy.
  • To identify key factors for developing effective myeloma immunotherapies.

Main Methods:

  • Analysis of T cell populations in myeloma patients.
  • Review of clinical immunization trial outcomes.
  • Examination of T cell tolerance and deletion mechanisms post-antigen presentation.

Main Results:

  • Expanded T cell clones are present in myeloma patients and linked to better survival.
  • Tumor-specific T cell isolation remains a significant hurdle.
  • Evidence suggests T cells may be tolerized or deleted, and tumor peptides may not be universally present.

Conclusions:

  • Effective immunotherapy for myeloma requires identifying suitable tumor antigens.
  • Understanding antigen presentation interactions is crucial.
  • Strategies to enhance autologous T cell cytotoxicity are needed for improved patient outcomes.

Related Experiment Videos